{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"ImmunoPrecise Antibodies Announces Key Leadership Changes - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"HP4K2z4MGO\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-announces-key-leadership-changes\/\">ImmunoPrecise Antibodies Announces Key Leadership Changes<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunoprecise-antibodies-announces-key-leadership-changes\/embed\/#?secret=HP4K2z4MGO\" width=\"600\" height=\"338\" title=\"&#8220;ImmunoPrecise Antibodies Announces Key Leadership Changes&#8221; &#8212; Market Newsdesk\" data-secret=\"HP4K2z4MGO\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"ImmunoPrecise Antibodies Announces Key Leadership Changes AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; ImmunoPrecise Antibodies (the \u201cCompany\u201d or \u201cIPA\u201d) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20250224016053\/en\/ Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA\u2019s Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its Board of Directors. With over 30 years of expertise in AI, semiconductor technologies, and global R&amp;D &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20250224016053\/en\/2390289\/4\/Photo_Kamil_Nov_22_1.jpg"}